Metastatic Esophageal Cancer | Unmet Need | US/EU | 2022
Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent approvals of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) as single agents and in combination with chemotherapy are beginning to change the treatment landscape. Nevertheless, substantial need remains for more-efficacious treatments for metastatic esophageal cancer, particularly for tumors with low PD-L1 expression.
QUESTIONS ANSWERED
- How satisfied are U.S. and European medical oncologists with current treatment options for metastatic esophageal cancer?
- What are the treatment drivers and goals most likely to influence the choice of therapy for metastatic esophageal cancer?
- How do current therapies, such as Keytruda and Opdivo, perform on key clinical attributes, and what are the hidden opportunities for drug developers in this patient population?
- What trade-offs are U.S. and European medical oncologists willing to make across key clinical attributes and pricing when considering hypothetical target product profiles for metastatic esophageal cancer?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in April 2022.
Key companies: Bristol Myers Squibb, Merck & Co.
Key drugs: Opdivo, Keytruda, and trastuzumab.
